drugset / Trial / NCT01525238
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
RandomizedParallel-groupOpen-labelOther
Summary
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
Timeline
- Start
- 2012-07-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 2.5 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 5 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |